Lilian Khalil, Arige Boubou, Nisrin Kaddar
firstname.lastname@example.org , email@example.com , firstname.lastname@example.org
Lilian Khalil1, Arige Boubou2, Nisrin Kaddar3
1Faculty of Pharmacy, Tishreen University, Lattakia, Syria.
2Faculty of Medicine, Tishreen University, Lattakia. Syria.
3Faculty of Pharmacy, Tishreen University, Lattakia, Syria.
Volume - 15,
Issue - 11,
Year - 2022
Diabetes is one of the most common metabolic diseases, linked to hyperuricemia. Several studies have shown that high serum uric acid levels (SUA) are associated with an increased risk of diabetes. SGLT2 inhibitors (Sodium Glucose Cotransporter-2 Inhibitors) are a new drug for diabetes treatment. In addition to their ability to lower blood glucose, they have other benefits, including lowering serum uric acid levels. This study aimed to evaluate the effect of dapagliflozin, which is a selective inhibitor of SGLT2 Cotransporters present in the kidneys, on serum uric acid levels in patients with type 2 diabetes, compared with a control group. The study included 51 patients with type 2 diabetes, randomly selected from an endocrinology clinic, who started dapagliflozin treatment 5 and 10 mg at recruitment. The control group included 64 patients with type 2 diabetes treated with metformin. Patients were monitored for 3-6 months and serum uric acid levels were measured at baseline and after follow-up. 3 months after treatment, the mean concentration of uric acid in the dapagliflozin group was lower than that of the metformin group (4.58 vs. 5.24 mg/dl p = 0.0143). At 6 months follow-up, SUA levels decreased by 0.79 mg/dL and it was statistically significant (p = 0.0004), compared with control group where there was no statistically significant change in SUA levels. Statistically, there was no significant difference in uric acid levels between doses 5 and 10 mg. However, decreasing in SUA levels with dapagliflozin 5 mg was greater than that occurred with dapagliflozin 10 mg after 6 months of treatment. In conclusion, Dapagliflozin results in a decrease of SUA levels in patients with type 2 diabetes by increasing urinary excretion of uric acid induced by SGLT2 inhibitors.
Cite this article:
Lilian Khalil, Arige Boubou, Nisrin Kaddar. Effect of Dapagliflozin on Serum Uric Acid in Type 2 Diabetes Mellitus patients. Research Journal of Pharmacy and Technology. 2022; 15(11):4994-8. doi: 10.52711/0974-360X.2022.00839
Lilian Khalil, Arige Boubou, Nisrin Kaddar. Effect of Dapagliflozin on Serum Uric Acid in Type 2 Diabetes Mellitus patients. Research Journal of Pharmacy and Technology. 2022; 15(11):4994-8. doi: 10.52711/0974-360X.2022.00839 Available on: https://rjptonline.org/AbstractView.aspx?PID=2022-15-11-24
1. Ahmed, D. and R. Makhous, Evaluation of the effect of Metformin therapy on TSH serum levels in Diabetic patients. Research Journal of Pharmacy and Technology, 2020 Jan. 13(8): 3801-3806. doi: 10.5958/0974-360x.2020.00673.3
2. Kamtekar, S. and V. Keer, Management of Diabetes: A Review. Research Journal of Pharmacy and Technology, 2014 Oct. 7(9): 1065-1072.
3. Association, A.D., Diagnosis and classification of diabetes mellitus. Diabetes care, 2010 Jan. 32(Supplement 1): S62-S69. doi.org/10.2337/dc10-S062
4. Sriram, S., A.A. Elizabeth, and L. Akila, Cost Analysis of SGLT2 Inhibitors in patients with type 2 Diabetes in India. Research Journal of Pharmacy and Technology, 2020 Dec. 13(12): 5861-5865. doi:10.5958/0974-360X.2020.01021.5
5. Preethikaa, S. and M. Brundha, Awareness of diabetes mellitus among general population. Research Journal of Pharmacy and Technology, 2018 Aug. 11(5): 1825-1829. doi : 10.5958/0974-360X.2018.00339.6
6. Bairagi, G., A. Kabra, and R. Mandade, Sexual Dysfunction in Men with Diabetes Mellitus. Research Journal of Pharmacy and Technology, 2011 Apr. 4(5): 677-684.
7. Frank, O., Management of Diabetes Mellitus with Combined Therapy of Reducdyn and Metformin in Streptozotocin-induced Diabetic Rats. Research Journal of Pharmacy and Technology, 2014 Jan. 7(1): 39-43.
8. Yuan, H.-J., et al., Association of serum uric acid with different levels of glucose and related factors. Chinese medical journal, 2011 May. 124(10): 1443-1448. doi: 10.3760/cma.j.issn.0366-6999.2011.10.001
9. Nakagawa, T., et al., Hypothesis: fructose-induced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome. Nature clinical practice Nephrology, 2005 Dec. 1(2): 80-86.
10. Shettigar, S.R. and V.G. Kanase, Evaluation of anti-hyperuricemic activity of the alcoholic extract of dried Capparis moonii wight fruits in wistar rats. Research Journal of Pharmacy and Technology, 2021 Jun. 14(6): 3173-3178. DOI:10.52711/0974-360X.2021.00553
11. Bhole, V., et al., Serum uric acid levels and the risk of type 2 diabetes: a prospective study. The American journal of medicine, 2010 Oct. 123(10): 957-961. doi.org/10.1016/j.amjmed.2010.03.027
12. Wang, J., et al., Prevalence and determinants of hyperuricemia in type 2 diabetes mellitus patients with central obesity in Guangdong Province in China. Asia Pacific journal of clinical nutrition, 2013 Jan. 22(4): 590-598.
13. Yuan, T., et al., Effects of dapagliflozin on serum and urinary uric acid levels in patients with type 2 diabetes: a prospective pilot trial. Diabetology & Metabolic Syndrome, 2020 Oct. 12(1): 1-9.
14. Lambers Heerspink, H., et al., Dapagliflozin a glucose‐regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes, Obesity and Metabolism, 2013 May. 15(9): 853-862. doi.org/10.1111/dom.12127
15. Kumari, M.S., et al., Diabetes Mellitus: Present status and Drug therapy Updates. Research Journal of Pharmacy and Technology, 2014 Mar. 7(1): 84-94.
16. Wright, E., B. Hirayama, and D. Loo, Active sugar transport in health and disease. Journal of internal medicine, 2007 Jan. 261(1): 32-43. doi.org/10.1111/j.1365-2796.2006.01746.x
17. List, J.F., et al., Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes care, 2009 Dec. 32(4): 650-657. doi.org/10.2337/dc08-1863
18. Komoroski, B., et al., Dapagliflozin, a novel SGLT2 inhibitor, induces dose‐dependent glucosuria in healthy subjects. Clinical Pharmacology & Therapeutics, 2009 Jan. 85(5): 520-526. doi.org/10.1038/clpt.2008.251
19. Munde, M.K., et al., A Comprehensive Review on Analytical Method Development and Validation for SGLT-2 Inhibitors by HPLC in Its API and Dosage Form. Research Journal of Pharmacy and Technology, 2020 Aug. 13(7): 3472-3479. DOI : 10.5958/0974-360X.2020.00616.2
20. Halimi, S. and B. Verges, Adverse effects and safety of SGLT-2 inhibitors. Diabetes & metabolism, 2014 Dec. 40(6): S28-S34. doi.org/10.1016/S1262-3636(14)72693-X
21. Kaku, K., et al., Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double‐blind, placebo‐controlled trial. Diabetes, Obesity and Metabolism, 2013 Nov. 15(5): 432-440. doi.org/10.1111/dom.12047
22. Chino, Y., et al., SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharmaceutics & drug disposition, 2014 Jul. 35(7): 391-404. doi.org/10.1002/bdd.1909
23. Lin, K.-C., H. Lin, and P. Chou, The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. The Journal of rheumatology, 2000 Jun. 27(6): 1501-1505.
24. Zoppini, G., et al., Elevated serum uric acid concentrations independently predict cardiovascular mortality in type 2 diabetic patients. Diabetes care, 2009 Jun. 32(9): 1716-1720. doi.org/10.2337/dc09-0625
25. Nisa, U., P.R.W. Astana, and H. Kuncoro, The effect of Antihypertensive Herb formula of Indonesian traditional medicines against serum uric acid levels in mild Hypertensive patients. Research Journal of Pharmacy and Technology, 2021 Jan. 14(1): 254-258. doi: 10.5958/0974-360X.2021.00045.7
26. Xu, Y., et al., Hyperuricemia as an independent predictor of vascular complications and mortality in type 2 diabetes patients: a meta-analysis. PloS one, 2013 Oct. 8(10): e78206. doi.org/10.1371/journal.pone.0078206
27. Ito, H., et al., Hyperuricemia is independently associated with coronary heart disease and renal dysfunction in patients with type 2 diabetes mellitus. PloS one, 2011 Nov. 6(11): e27817. doi.org/10.1371/journal.pone.0027817
28. Bailey, C.J., Renal glucose reabsorption inhibitors to treat diabetes. Trends in pharmacological sciences, 2011 Feb. 32(2): 63-71. doi.org/10.1016/j.tips.2010.11.011